Taken together, our findings suggest that IL-6 and RBP4 may function as biomarkers of poor prognosis and may represent potential therapeutic targets, particularly in CRC cases linked to inflammation and obesity. Here, RBP4 is linked to obesity due to melanocortin 4 receptor deficiency.